The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index; 27 of the 69 sources its claims cite were checked for support.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Open accessAbstract
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3-4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3-4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier: NCT04649359 .
Overview
CoChat Summary
TL;DR
Elranatamab monotherapy in the phase 2 MagnetisMM-3 cohort A produced a 61.0% confirmed objective response rate in 123 patients with relapsed or refractory multiple myeloma who had no prior BCMA-directed therapy. Responses were often deep and durable, with 35.0% achieving ≥CR, 60.5% of those ≥CR being MRD-negative, and safety being manageable though infections, CRS, and cytopenias were common.
Key findings
- In 123 treated patients, the confirmed objective response rate by blinded independent central review was 61.0% (75/123; 95% CI 51.8–69.6).
- Deep responses were frequent: 35.0% achieved ≥CR, 56.1% achieved VGPR or better, and among patients with ≥CR and evaluable MRD (n = 29), 89.7% were MRD-negative, corresponding to 60.5% of all patients with ≥CR.
- With median follow-up of 14.7 months, median duration of response, progression-free survival, and overall survival were not reached; 15-month estimates were 71.5% for maintaining response, 50.9% for PFS, and 56.7% for OS.
- Among 50 responders who switched to biweekly dosing at least 6 months before data cutoff, 80.0% maintained or improved response ≥6 months after the switch, and 40.0% deepened response, including 38.0% who improved to ≥CR.
- Safety: all 123 patients had treatment-emergent AEs; 70.7% had grade 3 or 4 events. Common AEs included infections (69.9%; 39.8% grade 3–4), CRS (57.7%; 0% grade 3–4), anemia (48.8%; 37.4% grade 3–4), and neutropenia (48.8%; 48.8% grade 3–4).
Methods
- Ongoing multicenter, open-label, single-arm phase 2 MagnetisMM-3 study of elranatamab monotherapy in relapsed or refractory multiple myeloma; this report covers cohort A (no prior BCMA-directed therapy), with 123 enrolled and treated patients across 47 sites in 10 countries.
- Eligible patients were adults with measurable disease, ECOG ≤2, adequate organ function, and disease refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody; treatment was subcutaneous elranatamab 76 mg weekly after 12 mg and 32 mg step-up doses, with responders switching to biweekly dosing after 6 cycles if PR or better persisted for at least 2 months.
- Primary endpoint was confirmed ORR by BICR; secondary endpoints included CR rate, MRD negativity, TTR, DOR, PFS, OS, safety, pharmacokinetics, and immunogenicity; analyses were descriptive with Kaplan–Meier methods for time-to-event outcomes.
Limitations
- The paper states the main limitations are the single-arm design, lack of direct comparison with other treatments, small sample sizes in some subgroups, and the need for longer follow-up to confirm DOR, PFS, and OS benefits.
- Evident from the text: results for biweekly dosing are not from a randomized QW comparator, so the authors note the safety change after switching cannot be cleanly interpreted.
- Evident from the text: the cohort reported here excludes patients with prior BCMA-directed therapy, so the findings do not address that population.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
13 Valid · 1 Not valid · 10 Not checked · 88 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody.”
- Also stated in: § Main · plain
“Elranatamab (PF-06863135) is a humanized bispecific antibody that targets both BCMA (on myeloma cells) and CD3 (on T cells)3.”
§ Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results > Abstract
What the sources say
- Partly supportedcites [3] Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020). sourceExperimental — accuracy not yet measured
The Bispecific antibody constructs section describes PF-06863135 (PF-3135) as a humanized antibody with anti-BCMA and anti-CD3 arms. Our copy does not name elranatamab or identify it as PF-06863135, so it does not establish that the description applies to elranatamab. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“outcomes for patients with disease progression after these agents remain poor with a median progression-free survival (PFS) of 4.6 months and median overall survival (OS) of 12.4 months with a standard of care therapy, highlighting an unmet medical need in the relapsed or refractory multiple myeloma population1.”
§ Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results > Main
What the sources say
- Supportedcites [1] Mateos, M. V. et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 36, 1371–1376 (2022). source
The Introduction identifies the study population as patients with relapsed or refractory multiple myeloma previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. The Results (Efficacy) report median progression-free survival of 4.6 months and median overall survival of 12.4 months with real-life standard-of-care therapy; the Discussion describes these outcomes as poor. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
§ Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results > Discussion
What the sources say
- Partly supportedcites [4] Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022). sourceExperimental — accuracy not yet measured
The Results (Efficacy; page not provided) report lower response rates among patients with stage III disease receiving teclistamab. However, the Results (Patients) identify the staging measure as the International Staging System, not R-ISS, and the Discussion notes that this small subgroup had wide confidence intervals. This single-treatment finding does not establish consistently poorer outcomes irrespective of therapy. (LLM, conf=0.88)
- Could not verifycites [5] Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021). sourceExperimental — accuracy not yet measured
The Efficacy section and subgroup figure include R-ISS stage III patients, but the available text does not establish that they had poorer outcomes than patients at other stages. The paper reports outcomes after ide-cel, not a consistent pattern irrespective of therapy; searches for stage-specific outcomes and therapy-independent prognosis found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [6] Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021). source
- Not checked — no full text of the sourcecites [19] Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–221 (2020). source
- Could not verifycites [20] Blade, J. et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12, 45 (2022). sourceExperimental — accuracy not yet measured
The Results > Incidence section mentions revised stage III only as a reason to suspect extramedullary disease and consider PET/CT. Results > Treatment outcomes discusses poorer outcomes for patients with extramedullary disease, but does not compare outcomes by R-ISS stage or establish that stage III patients fare worse regardless of therapy. Searches for “R-ISS,” “stage III,” and therapy-independent outcomes found no supporting passage. (LLM, conf=0.76)
- Supportedcites [21] Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863–2869 (2015). source
The Results (Combined ISS, CA and LDH; page not provided) show that R-ISS stage III had the poorest overall and progression-free survival. The subgroup analysis reports that R-ISS remained prognostic among patients who did and did not receive ASCT, proteasome inhibitors, or IMIDs; the Discussion describes its impact on overall survival as independent of therapy. (LLM, conf=0.92)
- Could not verifycites [22] Gill, S. K. et al. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 12, 138 (2022). sourceExperimental — accuracy not yet measured
The To the Editor section reports poorer outcomes for quad- or penta-refractory patients than for exposed patients, but it does not establish outcomes by R-ISS stage or across therapies. Searches for “R-ISS,” “stage III,” and staging-related survival findings found no passage addressing the claim about R-ISS stage III. (LLM, conf=0.74)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
§ Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results > Discussion
What the sources say
- Partly supportedcites [4] Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022). sourceExperimental — accuracy not yet measured
The Results > Safety passage reports hematologic adverse-event rates for teclistamab, and Results > Efficacy gives a median follow-up of 14.1 months. These provide comparator data, but this paper does not report elranatamab rates or establish that they were similar or lower after a similar follow-up. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [5] Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021). sourceExperimental — accuracy not yet measured
The Safety section and Table 2 report hematologic adverse-event rates for idecabtagene vicleucel, providing data for one therapy in the comparison. This paper does not report elranatamab outcomes or establish that its rates were similar or lower after a similar follow-up. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BCMA-targeted T-cell-redirecting therapies have been linked to a heightened susceptibility to infectious complications due to their mechanism of action30–33.”
§ Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results > Discussion
What the sources say
- Partly supportedcites [30] Sim, B. Z. et al. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 13, 34 (2023). sourceExperimental — accuracy not yet measured
The Discussion reports substantial infection rates in trials of T-cell/BCMA-targeting bispecific antibodies, supporting the link to infectious complications. It does not establish that their mechanism of action causes heightened susceptibility; the authors also note that infection rates in their heavily treated cohort were comparable to those with other therapies. No page number is available in our copy. (LLM, conf=0.84)
- Partly supportedcites [31] Mazahreh, F. et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 7, 3069–3074 (2023). sourceExperimental — accuracy not yet measured
The Results report more severe infections with BCMA-targeting than non-BCMA bispecific antibodies, and the Discussion describes treatment-related immune changes that increase infection risk. However, the Discussion says infections may be related to the underlying myeloma, prior therapies, and/or the antibodies’ mechanism of action; it does not establish that the mechanism is the cause. Page numbers were not supplied in our copy. (LLM, conf=0.84)
- Partly supportedcites [32] Kambhampati, S. et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 6, 2045–2054 (2022). sourceExperimental — accuracy not yet measured
The Abstract reports infections in 29 of 55 patients after BCMA CAR-T, and the Introduction lists infections among CAR-T-associated toxicities. But the study concerns BCMA CAR-T specifically, not all BCMA-targeted T-cell-redirecting therapies, and it does not establish that their mechanism of action caused heightened infection susceptibility. Page numbers were not available in our copy. (LLM, conf=0.86)
- Not checked yetcites [33] Mikkilineni, L. et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 5, 5312–5322 (2021). source
Checked before — its earlier verdict is held back until a new check runs.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
53 more claims · 2 with their cited sources checked
Create a free account to see all 112 claims and to verify the 2 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The objective response rate of Elranatamab reach to 61.0% (75 out of 123 patients); with 35.0%≥CR, and 80.0% of patients maintained their response for at least 6 months [211].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [211]
Experimental — accuracy not yet measured
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationPalumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 2×
“Includes t(4;14), t(14;16) and del(17p) chromosomal abnormalities.”
BackgroundSelf-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citation
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
“…1 CD20-TCE epcoritamab 109 were approved for treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL), as well as the 1 + 1 G-protein-coupled receptor class C group 5 member D (GPRC5D)-TCE talquetamab 110 and BCMA-TCE elranatamab 111 for relapsed/refractory multiple myeloma (Table 1).”
Bispecific T cell engager therapy for refractory rheumatoid arthritis
Bucci, L., Hagen, M., Rothe, T., Raimondo, M. G., Fagni, F., Tur, C., Wirsching, A., Wacker, J., Wilhelm, A., Auger, J.-P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02964-1 · Cited by 186
“The use of such BCMAxCD3 BiTEs, such as teclistamab and elranatamab, has been approved in the treatment of multiple myeloma 27,28 .”
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01008 · Cited by 186
Self-citationBispecific antibodies: advancing precision oncology
Herrera, M., Pretelli, G., Desai, J., Garralda, E., Siu, L. L., Steiner, T. M., & Au, L. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2024.07.002 · Cited by 178
Metadata
- Authors
- Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., Jethava, Y., Quach, H., Depaus, J., Yokoyama, H., Gabayan, A. E., Stevens, D. A., Nooka, A. K., Manier, S., Raje, N., Iida, S., Raab, M.-S., Searle, E., Leip, E., Sullivan, S. T., Conte, U., Elmeliegy, M., Czibere, A., Viqueira, A., & Mohty, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Iowa (US)
- Hôpital Saint-Louis (FR)
- University of Calgary (CA)
- Centre Hospitalier Universitaire de Nantes (FR)
- The University of Melbourne (AU)
- UCLouvain (BE)
- Tohoku University (JP)
- Beverly Hills Cancer Center (US)
- Norton Healthcare (US)
- Winship Cancer Institute (US)
- Inserm (FR)
- Harvard University (US)
- Nagoya City University (JP)
- University Hospital Heidelberg (DE)
- University of Manchester (GB)
- Pfizer (United States) (US)
- Pfizer (Spain) (ES)
- Corresponding author
- Lesokhin, Alexander M.
- ORCID
- Lesokhin, Alexander M.
- Tomasson, Michael H.
- Arnulf, Bertrand
- Bahlis, Nizar J.
- Miles Prince, H.
- Martinez-Lopez, Joaquin
- Koehne, Guenther
- Touzeau, Cyrille
- Jethava, Yogesh
- Quach, Hang
- Yokoyama, Hisayuki
- Nooka, Ajay K.
- Manier, Salomon
- Raje, Noopur
- Iida, Shinsuke
- Raab, Marc-Steffen
- Searle, Emma
- Sullivan, Sharon T.
- Elmeliegy, Mohamed
- Mohty, Mohamad
- Venue
- Nature Medicine
- Published
- 2023-08-15
- Volume
- 29
- Issue
- 9
- Pages
- 2259-2267
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10504075
- OpenAlex
- W4385839624
- Semantic Scholar
- a55507ebe804052e3b521e7acb8f3139db15bbe0
- Cited by
- 664
- References
- 38
- Citations by year
- 2026: 213 · 2025: 242 · 2024: 181 · 2023: 28
- FWCI
- 136.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida) (submittedVersion, cc-by)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- elranatamab, relapsed/refractory multiple myeloma, BCMA-CD3 bispecific antibody, BCMA, subcutaneous dosing, biweekly dosing, objective response rate, progression-free survival, overall survival, cytokine release syndrome, adverse events
- MeSH terms
- Progression-Free Survival, Humans, Multiple Myeloma, Remission Induction, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. https://app.cochat.ai/papers/10.1038/s41591-023-02528-9
- The paper
- Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., Jethava, Y., Quach, H., Depaus, J., Yokoyama, H., Gabayan, A. E., Stevens, D. A., Nooka, A. K., Manier, S., Raje, N., . . . Mohty, M. (2023). Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature Medicine. https://doi.org/10.1038/s41591-023-02528-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.